Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells

Cisplatin is a known antitumor drug, but its mechanisms of action are not fully elucidated. In this research, we studied the anticancer potential of cisplatin at doses of 1, 2, or 3 μM using HL-60 cells as a test model. We investigated cisplatin effects at the molecular level using RNA sequencing, c...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker Insights 2016-01, Vol.2016 (11), p.113-121
Main Authors: Velma, Venkatramreddy, Dasari, Shaloam R., Tchounwou, Paul B.
Format: Article
Language:English
Subjects:
Antitumor activity
Apoptosis
Cell cycle
Cisplatin
DNA biosynthesis
G1 phase
Gene expression
Original Research
Promyeloid leukemia
Ribonucleic acid
RNA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cisplatin is a known antitumor drug, but its mechanisms of action are not fully elucidated. In this research, we studied the anticancer potential of cisplatin at doses of 1, 2, or 3 μM using HL-60 cells as a test model. We investigated cisplatin effects at the molecular level using RNA sequencing, cell cycle analysis, and apoptotic assay after 24, 48, 72, and 96 hours of treatment. The results show that many genes responsible for molecular and cellular functions were significantly altered. Cisplatin treatment also caused the cells to be arrested at the DNA synthesis phase, and as the time increases, the cells gradually accumulated at the sub-G1 phase. Also, as the dose increases, a significant number of cells entered into the apoptotic and necrotic stages. Altogether, the data show that low doses of cisplatin significantly impact the viability of HL-60 cells, through modulation of gene expression, cell cycle, and apoptosis.
ISSN:1177-2719
1177-2719
DOI:10.4137/BMI.S39445